Aterian, Inc. quarterly report, Q1 FY2023

Aterian, Inc. — Q1 2023 Form 10-Q

Reporting period: Three months ended March 31, 2023. Aterian is a technology-enabled consumer products company selling primarily through online retailers, especially Amazon. Unless stated otherwise, financial amounts below are in millions of dollars.

Financial performance

  • Revenue: $34.9, down 16.3% from $41.7 in Q1 2022. Direct revenue fell 16.7% to $33.4; wholesale revenue fell 7.0% to $1.5. Management attributed the overall decline primarily to softer consumer demand in the macroeconomic environment. Organic direct revenue increased 11.7% to $33.3, while revenue classified as M&A businesses fell to $0.1 from $9.6, partly reflecting businesses moving into the organic category after one year.
  • Gross profit and margin: Gross profit was $19.1, down 19.1%; gross margin was 54.8%, versus 56.6%. Management cited product mix, supply-chain costs, and discounted liquidation of higher-priced excess inventory.
  • Operating expenses and loss: Operating expenses were $44.1, including a $16.7 noncash impairment of essential-oil trademarks. Operating loss was $25.0, compared with $36.3 in Q1 2022, which included a $29.0 goodwill impairment. Net loss improved to $25.8 from $42.8; diluted loss per share was $0.34 versus $0.78.
  • Profitability measures: Contribution margin was $2.1, or 5.9% of revenue, compared with $3.8, or 9.2%. Adjusted EBITDA was a loss of $4.3 versus a loss of $4.5; as a percentage of revenue it worsened to (12.2)% from (10.9)%. These are company-defined non-GAAP measures.
  • Cash flow: Operating cash used was $7.4, compared with $13.2 in Q1 2022. Investing cash used was $0.2; financing cash used was $3.0, principally net MidCap repayments, seller-note repayment, and insurance payments. Cash and restricted cash decreased $10.4 to $36.2, including $33.9 unrestricted cash and $2.3 restricted cash.
  • Liquidity and debt: Current assets were $84.6 and current liabilities $42.4 at March 31. The credit facility’s gross balance was $19.8 and carrying value, net of deferred financing costs and warrant discount, was $19.1. The company reported only $0.3 of facility availability. The revolving facility is up to $40.0, subject to its borrowing base, and bears interest at Term SOFR plus 5.60% (including the 0.10% SOFR adjustment).
  • Other balance-sheet metrics: Inventory was $40.4, down from $43.7 at year-end 2022. Total assets were $122.6, stockholders’ equity $78.8, and accumulated deficit $651.1.

Material changes, outlook, and risks

  • Revenue declined across every reported product category. Kitchen-appliance revenue fell to $6.4 from $8.5; management said certain key products lost ranking on Amazon, reducing demand. Sales and distribution costs declined in dollars but rose to 58.0% of revenue from 55.1%, with higher fulfillment and last-mile shipping costs also weighing on margins.
  • Leadership changes in the essential-oil business led to a reduced planned product portfolio and revised forecasts. Aterian recorded a $16.7 impairment after estimating trademark fair value using Level 3 inputs. Further impairment is possible if operating expectations do not materialize.
  • Going concern: The filing says recurring losses and operating cash outflows, dependence on outside capital, covenant risks, and lack of firm commitments for additional capital raise substantial doubt about the company’s ability to continue as a going concern. Management warned it may be unable to meet obligations over the next 12 months without operating cash inflows and/or additional capital. It was in compliance with MidCap covenants at March 31 and expected compliance through at least March 31, 2024, but gave no assurance. The minimum-liquidity covenant is $12.5 during February–May and $15.0 otherwise; noncompliance could permit acceleration of debt or enforcement against collateral.
  • No specific financial guidance was provided. Management described ongoing uncertainty around consumer demand, inflation, tariffs, and supply-chain and shipping costs. It identified possible spending delays, reduced product investment, reduced distribution infrastructure, asset sales, divestitures, or broader strategic alternatives if its plans are unsuccessful.
  • Subsequent events: Nasdaq notified Aterian on April 24, 2023 that its share price had not met the $1.00 minimum bid requirement for 30 consecutive business days. The initial cure period ran through October 23, 2023; delisting risk remained if compliance was not regained. On May 9, Aterian announced workforce reductions affecting approximately 70 employees and 30 contractors, expecting about $6.0 annualized savings and $1.0–$1.3 in restructuring charges, primarily in Q2 2023.
  • Contingencies: Aterian recorded about $0.8 for estimated sales-tax exposure. It paid $0.3 in Q1 to settle shareholder derivative actions, which also required corporate-governance reforms. A supplier settlement remains disputed and reserved; a related legal action is stayed pending bankruptcy proceedings. A separate earn-out payment dispute is subject to a motion to compel arbitration. The company also disclosed a previously accrued Mueller product-marketing settlement and other ordinary-course legal matters.
  • Additional risks include substantial reliance on Amazon’s U.S. marketplace and its policies, the possibility of seller-account or listing restrictions, and challenges attracting or retaining key personnel. Management reported disclosure controls were effective as of March 31, 2023.

Most important facts to verify

  • Cash runway, expected cash needs, and whether Aterian can obtain financing or generate sufficient operating cash to address the disclosed going-concern uncertainty.
  • MidCap borrowing-base availability, liquidity-covenant headroom, and the consequences of any covenant breach or waiver requirement.
  • Whether revenue, contribution margin, and product rankings stabilize, particularly on Amazon, and whether shipping and fulfillment costs ease.
  • The assumptions supporting the $16.7 trademark impairment and the potential for additional impairments or inventory write-downs.
  • Progress toward Nasdaq bid-price compliance and the actual savings, timing, and charges from the workforce reduction.
  • Potential cash exposure and resolution status of the supplier, earn-out, tax, and other legal matters.